MEDAG and breast carcinoma: The CCK-8 results showed that the cell viability of the MEDAG knockdown and control groups did not differ at 12 h, but MEDAG knockdown significantly promoted the inhibitory effect of epirubicin on the proliferation of breast cancer cells (Fig. 7D).